Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), one of the world’s leading fixed-dosage injectable manufacturers, has received marketing authorization from Indonesia’s regulatory authority for its combination antibiotic, Ceftazidime + Avibactam.
First Anti-Infective Approval and Generic Launch in Indonesia
This approval marks Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia. Moreover, it enables the country’s first generic launch of Ceftazidime + Avibactam. As a result, the milestone represents a significant step in the company’s international expansion strategy and strengthens its regulatory and commercial presence across Southeast Asia.
Strengthening Footprint Across ASEAN Markets
Furthermore, the authorization reinforces Venus Remedies’ growing presence in ASEAN markets. Currently, the company operates commercially in 10 ASEAN countries and holds more than 370 injectable approvals across the region. This development aligns with Venus Remedies’ focus on expanding access to advanced critical-care therapies while supporting India’s role as a reliable supplier of high-quality injectable pharmaceuticals to emerging healthcare markets.
Leadership Emphasises Focus on Antimicrobial Resistance
Commenting on the development, Saransh Chaudhary, President – Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftazidime + Avibactam in Indonesia is an important regulatory milestone for Venus Remedies. It reflects our continued focus on addressing antimicrobial resistance through clinically relevant therapies designed for hospital-based care and reinforces our commitment to expanding access to life-saving anti-infective treatments in international markets.”
Advanced Therapy for Multidrug-Resistant Infections
Ceftazidime + Avibactam is an advanced antibiotic combination indicated for treating serious multidrug-resistant bacterial infections. These include complicated intra-abdominal infections and complicated urinary tract infections caused by gram-negative pathogens such as Pseudomonas aeruginosa and Enterobacteriaceae. Avibactam inhibits key beta-lactamase enzymes, thereby restoring the effectiveness of ceftazidime against resistant strains and addressing a critical unmet need in antimicrobial resistance management.
Indonesia Emerges as a Strategic Market
Indonesia stands as one of Southeast Asia’s largest pharmaceutical markets, where antibiotics remain a vital therapeutic category due to the high burden of infectious diseases and the growing emphasis on antimicrobial stewardship. Meanwhile, the broader ASEAN pharmaceutical market is projected to exceed USD 63.5 billion by 2029, underscoring the region’s increasing strategic importance for India’s pharmaceutical exports and healthcare partnerships.
Expanding Beyond Oncology in Indonesia
Highlighting the company’s long-term vision, Aditi K. Chaudhary, President – International Business, Venus Remedies Limited, said, “With the approval of Ceftazidime + Avibactam, Venus Remedies enters the anti-infective segment in Indonesia, expanding beyond our existing presence in oncology. Indonesia is a priority market for us, and this milestone reflects our commitment to building a compliant, scalable, and sustainable business in the region.”
Improving Access to Critical-Care Antibiotics
As per the press release, As the first generic of its kind in Indonesia, Ceftazidime + Avibactam is expected to significantly improve access to advanced anti-infective therapy in hospital and critical-care settings. Consequently, the approval strengthens Venus Remedies’ commercial platform across ASEAN and highlights Southeast Asia’s growing contribution to the company’s international business.
Asia Drives Strong Growth for Venus Remedies
With Asia continuing to grow at over 30% year-on-year for Venus Remedies, the company remains focused on expanding access to advanced injectable therapies. Through trusted local partnerships, resilient supply chains, and a disciplined international business strategy, Venus Remedies continues to reinforce India’s position as a dependable partner in combating antimicrobial resistance across emerging healthcare markets.